Daniel S. Levine

Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.

[Daniel S. Levine @dslevine]

Rare disease diagnosis is at a turning point. Long-read HiFi sequencing is boosting diagnostic yield by 10–15% by capturing structural variants, epigenetics, and regulatory signals—making the case for first-line use. @PacBio CEO Christian Henry explains: https://t.co/fOe6pR4LKr

[Daniel S. Levine @dslevine]

Most antibodies act as antagonists—but biology isn’t that simple. @MetaphoreBio's function-first platform uses live-cell data + ML to design antibodies that agonize, bias, or multi-target pathways. CEO Angela Hwang explains: https://t.co/CIt4NfEm0R

[Daniel S. Levine @dslevine]

FARA CEO Jen Farmer and @Solid_Bio CMO Gabriel Brooks explore the lived reality of Friedreich’s ataxia, the promise of next-generation gene therapy, and how true patient industry partnerships can shape trial design and development. @GlobalGenes
https://t.co/gTwQ2ptc70

[Daniel S. Levine @dslevine]

Cells constantly sense and respond to stress—adapting, recovering, or dying. Soley uses AI to map these responses at scale, unlocking “undruggable” targets. Soley's Yerem Yeghiazarians discusses their platform, pipeline, and first-in-class candidates.
https://t.co/meRr2ndQvl

[Daniel S. Levine @dslevine]

Winsights' Kasey Walsh discusses her daughter's ultra-rare genetic disorder diagnostic journey, gaps in how the patient experience informs drug development, and the Winsights data platform empowers rare disease communities to drive research priorities.
https://t.co/hUhwXL3WdO

[Daniel S. Levine @dslevine]

@EricElenko @PureTechH discusses the company’s disciplined approach to rescuing promising but discontinued therapeutics, its hub‑and‑spoke structure, and how this model can turn partially derisked assets into commercial successes.
https://t.co/6aTWufIXFl

[Daniel S. Levine @dslevine]

Trialport's Keith Berelowitz discusses his vision for a future where clinical trials are routinely discussed alongside standard of care, the gap between clinical trial availability and patient awareness, and how the Trialport platform informs patients.
https://t.co/rCrjqiP4GB

[Daniel S. Levine @dslevine]

Most cancer therapies hit 1 or 2 pathways, giving tumors a chance to adapt. Nuago CEO Robert Schickel discusses how his company is developing short RNAs to silence multiple survival genes at once—aiming for more durable tumor killing with less toxicity.
https://t.co/omP2EG9Rt8

[Daniel S. Levine @dslevine]

John Wollman @KomodoHealth discusses how the company and @GeneDx are leveraging longitudinal patient data with genomic and phenotypic data to shorten rare disease diagnostic odysseys, accelerate natural hist studies, and enable better clinical decisions.
https://t.co/Lu91t2Hmbw

[Daniel S. Levine @dslevine]

Crystalis CEO James Mackay discusses gout, why therapies often fail to get uric acid to target levels, and how the company’s next‑generation URAT1 inhibitor may fill the treatment gap and change daily life for patients living with moderate to severe gout.
https://t.co/gw9MhfTY56

[Daniel S. Levine @dslevine]

@Bayer CDIO @BijoyCido discusses why AI must be treated as a tool to solve defined business problems, why prompt engineering is an ongoing process rather than a one-shot querry, and how expert teams are empowered to experiment and build AI solutions .
https://t.co/FSVGhL89IX

[Daniel S. Levine @dslevine]

Genome sequencing is moving from last resort to frontline in rare disease care. Akash Kumar of MyOme explains what it means for treatment decisions, trial access, and the emotional burden on families searching for a diagnosis. @GlobalGenes #RARECast
https://t.co/jLC4E0kM9C

[Daniel S. Levine @dslevine]

When inflammation spirals out of control, traditional drugs often don’t work. @Mesoblast's Ryoncil—the first MSC therapy in the US—targets GVHD in children. CEO @DrItescu discusses how MSCs can calm cytokine storms and what’s next for the platform.
https://t.co/CfjfEqzVqG

[Daniel S. Levine @dslevine]

@NicoleZJohnson1 and @nashafitter1 , co-founders of @Foxg1Research , turned a parent-driven effort into a virtual biotech advancing a gene therapy into the clinic. They discuss lessons learned. @GlobalGenes #RARECast https://t.co/YQplFqCj0f

[Daniel S. Levine @dslevine]

Most MS drugs control relapses—but don’t stop the neurodegeneration driving long-term disability. Daniel Vitt, CEO of @ImmunicInc discusses how his company’s experimental once-daily oral therapy targets both inflammation and neuronal damage.

https://t.co/18Nij63348

[Daniel S. Levine @dslevine]

Jim Foote, CEO of First Ascent Biomedical, explains how combining genomics, functional assays, and AI could transform rare pediatric cancer care @GlobalGenes #RARECast
https://t.co/p0Aw6makIP

[Daniel S. Levine @dslevine]

@garidel_de CEO of @Abivax_ discusses how a once-failed HIV drug evolved into a late stage oral IBD therapy that may deliver durable remission, how it acts upstream of key inflammatory pathways, and its potential in a crowded but underserved IBD market.

https://t.co/Q0EBSK3Xet

[Daniel S. Levine @dslevine]

Pablo Sardi @sanofi discusses the potential of the oral BTK inhibitor rilzabrutinib to treat multiple rare autoimmune conditions, and how this strategy could shift the field from treating symptoms to targeting root causes of these conditions. @GlobalGenes
https://t.co/lfjnzY24ll

[Daniel S. Levine @dslevine]

Dennis Salotti @JazzPharma discusses how use of AI for mundane but high-impact work speeds studies and improves trial-site experience and how AI can be a thinking partner, rather than a shortcut, to elevate people from doers to critical thinkers.
https://t.co/nHsdoycrWq

[Daniel S. Levine @dslevine]

For people with Lynch syndrome, cancer is often a question of when—not if. Nouscom CEO Marina Udier discusses the company’s efforts to develop cancer vaccines to stop tumors before they start by training the immune system to recognize early cancer signals.
https://t.co/tIPLZ566Xb